Sio Gene Therapies Stock News

Geode Capital Management LLC increased its position in Sio Gene Therapies Inc. (NASDAQ:SIOX) by 752.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 408,087 shares of the companys stock after purchasing an additional 360,218 shares during the period. Geode []

Shares of Sio Gene Therapies Inc. (NASDAQ:SIOX) have been assigned a consensus recommendation of Buy from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price objective among []

Sio Gene Therapies (NASDAQ:SIOX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. []

Zacks Investment Research lowered shares of Sio Gene Therapies (NASDAQ:SIOX) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative []

In the last trading session, 1.33 million Sio Gene Therapies Inc. (NASDAQ:SIOX) shares changed hands as the companys beta touched 1.54. With the companys per share price at $1.99 changed hands at -$0.02 or -1.00% during last session, the market valuation stood at $146.60M. SIOXs last price was a discount, traded about -108.54% off its Sio Gene Therapies Inc. (NASDAQ: SIOX) Is The Most Intriguing Stock Today. Read More »

Sio used to be called Axovant - an unsuccessful biotech that attempted to bring several therapies to market, including an Alzheimer's treatment.

SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving o

These under $4 penny stocks could be worth taking a look at The post Top Penny Stocks to Buy Now? 3 Under $4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

The stock price of Sio Gene Therapies Inc (NASDAQ: SIOX) increased by over 14% pre-market today. This is why it happened.

Are these 'must watch' penny stocks on your list right now? The post 3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss n

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve

-  Study has now enrolled a total of nine patients across low-dose and high-dose cohorts -  On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1

Two new sample breakout stocks for Week 26 with better than 10% short-term upside potential. This past week, the peak gains were in PDSB +18.6% and FSTX +6.7% with Market and S&P 500 Momentum Gauges t